Industry Briefs: August 6, 2012 - Pharmaceutical Technology

Latest Issue
PharmTech

Latest Issue
PharmTech Europe

Industry Briefs: August 6, 2012
A roundup of additional company and people news from pharmaceutical and biopharmaceutical companies, their suppliers, and contract-service providers.


Company News

Accenture has agreed to acquire Octagon Research Solutions. Read More

FDA has issued a Complete Response Letter to Baxter International for HyQ, an investigational combination immunoglobulin product for treating primary immunodeficiencies. Read More

DKSH has agreed to divest OLIC, a CMO to Fuji Pharma. Read More

Bristol-Myers Squibb has announced the expiration of the Hart-Scott-Rodino waiting period for its acquisition of Amylin Pharmaceuticals. Read More

GlaxoSmithKline has completed its $3.6-billion acquisition of Human Genome Sciences. Read More

Isis Pharmaceuticals has successfully completed a pre-approval inspection by EMA of its manufacturing facility in Carlsbad, California, thereby allowing Isis to supply Genzyme with mipomersen sodium, the drug substance in Kynamro. Read More

Johnson & Johnson has discontinued Phase III clinical development of bapineuzumab intravenous (IV), a drug to treat mild-to-moderate Alzheimer’s disease and will take a charge of between $300 million and $400 million in the third quarter 2012. Read More

NIH National Institute of Allergy and Infectious Diseases (NIAID) has awarded Advanced BioScience Laboratories a contract to provide NIAID with preclinical development and cGMP manufacturing support for multiple vaccine and biologic products identified by NIAID program staff. Read More

Sanofi and Regeneron Pharmaceuticals have received FDA approval for their a new biologic drug, Zaltrap (ziv-aflibercept) for use in combination with a FOLFIRI (folinic acid, fluorouracil, and irinotecan) chemotherapy for treating colorectal cancer. Read More

ViroPharma has received FDA approval for industrial-scale manufacturing of Cinryze (C1 esterase inhibitor [human]), a nanofiltered plasma-derived C1 esterase inhibitor product.

People Notes

Advantar Laboratories has named Dave Bergstrom as chief operating officer. Read More

Cytovance Biologics has appointed Don Wuchterl as senior vice-president of manufacturing operations. Read More

Teva Pharmaceutical has appointed Carlo De Notaristefani as president and CEO of global operations, and Aharon (Arik) Yaari as executive vice-president of community and institutional affairs. Read More

ADVERTISEMENT

blog comments powered by Disqus
LCGC E-mail Newsletters

Subscribe: Click to learn more about the newsletter
| Weekly
| Monthly
|Monthly
| Weekly

Survey
FDASIA was signed into law two years ago. Where has the most progress been made in implementation?
Reducing drug shortages
Breakthrough designations
Protecting the supply chain
Expedited reviews of drug submissions
More stakeholder involvement
Reducing drug shortages
27%
Breakthrough designations
9%
Protecting the supply chain
41%
Expedited reviews of drug submissions
9%
More stakeholder involvement
14%
View Results
Jim Miller Outsourcing Outlook Jim Miller Health Systems Raise the Bar on Reimbursing New Drugs
Cynthia Challener, PhD Ingredients Insider Cynthia ChallenerThe Mainstreaming of Continuous Flow API Synthesis
Jill Wechsler Regulatory Watch Jill Wechsler Industry Seeks Clearer Standards for Track and Trace
Siegfried Schmitt Ask the Expert Siegfried SchmittData Integrity
Sandoz Wins Biosimilar Filing Race
NIH Translational Research Partnership Yields Promising Therapy
Clusters set to benefit from improved funding climate but IP rights are even more critical
Supplier Audit Program Marks Progress
FDA, Drug Companies Struggle with Compassionate Use Requests

Click here